Stockscreener 앱 받기
0.9414
3.79%
-0.0371
시간 외 거래:
.96
0.0186
+1.98%
전일 마감가:
$0.9785
열려 있는:
$0.9493
하루 거래량:
1.27M
Relative Volume:
0.89
시가총액:
$213.91M
수익:
-
순이익/손실:
$-179.82M
주가수익비율:
-0.7078
EPS:
-1.33
순현금흐름:
$-159.16M
1주 성능:
-18.84%
1개월 성능:
-20.22%
6개월 성능:
-6.79%
1년 성능:
-15.19%
1일 변동 폭
$0.915
$0.9735
1주일 범위
$0.915
$1.22
52주 변동 폭
$0.4993
$1.55
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
GOSS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.9414 | 213.91M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
Charles Schwab Investment Management Inc. Raises Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Is Gossamer Bio Inc. (GOSS) the Popular Penny Stock on Robinhood to Watch? - MSN
Cantor Fitzgerald Comments on Gossamer Bio FY2025 Earnings - Defense World
Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5? - Insider Monkey
Gossamer Bio Inc (NASDAQ: GOSS) Analysts Think Could Fell -290.62% From Current Levels - Stocks Register
Gossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to Analysts - Yahoo Finance
Gossamer Bio, Inc. (NASDAQ:GOSS) Position Decreased by Victory Capital Management Inc. - Defense World
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
10 Hot Biotech Stocks Under $5 - Insider Monkey
Q1 EPS Estimates for Gossamer Bio Reduced by HC Wainwright - Defense World
FY2028 EPS Forecast for Gossamer Bio Decreased by Analyst - Defense World
GOSSAMER BIO Earnings Preview: Recent $GOSS Insider Trading, Hedge Fund Activity, and More - Nasdaq
H.C. Wainwright maintains Buy on Gossamer Bio, $10 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Gossamer Bio, $10 target - Investing.com
Wedbush Reiterates Outperform Rating for Gossamer Bio (NASDAQ:GOSS) - Defense World
Gossamer Bio Reports 2024 Financial Results and Progress - TipRanks
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Gossamer Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Gossamer Bio shares rise on Q4 earnings beat By Investing.com - Investing.com South Africa
Gossamer Bio shares rise on Q4 earnings beat - Investing.com India
Gossamer Bio Inc (GOSS) Q4 Earnings: EPS Loss of $0.15 Beats Est - GuruFocus.com
Gossamer Bio: Q4 Earnings Snapshot - mySA
Gossamer Bio earnings beat by $0.02, revenue topped estimates - Investing.com UK
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - The Bakersfield Californian
3 Promising Penny Stocks With Over $100M Market Cap - Simply Wall St
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) -March 07, 2025 at 05:47 pm EST - Marketscreener.com
Can Gossamer Bio's Latest Stock Options Package Attract Top Talent in Biotech? - Stock Titan
With 60% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners - Yahoo Finance
Gossamer Bio (GOSS) Projected to Post Quarterly Earnings on Tuesday - Defense World
You Should Read This Analysis Before Investing in Gossamer Bio Inc (NASDAQ:GOSS) - US Post News
Gossamer Bio Inc (NASDAQ: GOSS) Up 11.11% This Year: What Is Going To Happen Next - Stocks Register
Gossamer Bio regains Nasdaq compliance with bid price - Investing.com
Gossamer Bio Is A Good Speculative 'Buy' On Seralutinib For PAH And PH-ILD (NASDAQ:GOSS) - Seeking Alpha
Understanding Gossamer Bio Inc Inc. (GOSS) Price Performance Through Chart Patterns - The InvestChronicle
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
GOSS Stock Sees Surge of Approximately 15.18% in Last Five Days - Knox Daily
Gossamer Bio Inc (NASDAQ: GOSS) Stock Gained 1.83% Over A Month – Any Room To Run? - Marketing Sentinel
Gossamer Bio showcases seralutinib studies at PVRI Congress - MSN
Are Smart Investors Making the Right Decision? Gossamer Bio Inc (GOSS) - SETE News
Gossamer Bio Inc (GOSS) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Octagon Capital Advisors LP Increases Stake in Gossamer Bio Inc - GuruFocus.com
Real-Time Update: Gossamer Bio Inc (GOSS) Stock Navigates the Market with Up-to-Date Data - The News Heater
Investor’s Delight: Gossamer Bio Inc (GOSS) Closes Weak at 1.02, Down -0.97 - The Dwinnex
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):